Arch Oncology

OverviewSuggest Edit

Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of antibody therapies for the treatment of patients with cancer. The Company's lead product candidate AO-176 is in Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, Arch Oncology is advancing pipeline programs, including anti-signal regulatory protein (SIRP) antibodies.

TypePrivate
Founded2006
HQBrisbane, CA, US
Websitearchoncology.com

Latest Updates

Employees (est.) (Sept 2021)27(-6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Arch Oncology

John McKearn

John McKearn

Chairman
Daniel Pereira

Daniel Pereira

Chief Scientific Officer
Arun Kashyap

Arun Kashyap

Vice President, Research
Vicki Sung

Vicki Sung

Vice President, Translational Medicine
Show more

Arch Oncology Office Locations

Arch Oncology has offices in Brisbane and St. Louis
Brisbane, CA, US (HQ)
2000 Sierra Point Pkwy #700Brisbane
St. Louis, MO, US
4340 Duncan Ave #301
Show all (2)

Arch Oncology Financials and Metrics

Summary Metrics

Founding Date

2006

Arch Oncology total Funding

$155 m

Arch Oncology latest funding size

$105 m

Time since last funding

5 months ago

Arch Oncology investors

Arch Oncology's latest funding round in May 2021 was reported to be $105 m. In total, Arch Oncology has raised $155 m
Show all financial metrics

Arch Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Arch Oncology Online and Social Media Presence

Embed Graph

Arch Oncology News and Updates

Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments

– Seasoned oncology leaders Louie Naumovski, M.D., Ph.D., appointed as Chief Medical Officer; Amit Agarwal, M.D., Ph.D. as Senior V.P., Clinical Development and Steve DeMattos as Senior V.P., Clinical Operations –

Arch Oncology Secures $105 Million Series C Financing

– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies –

Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021

-- Late-breaking presentation highlights preclinical data for AO-176 in T-ALL -- -- Late-breaking presentation highlights preclinical data for AO-176 in T-ALL --

Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO

BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Off…

Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021

-- Two presentations to highlight AO-176’s potential in lymphoma and T-ALL -- BRISBANE, Calif. and ST. LOUIS, March 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced t…

Arch Oncology to Participate in Upcoming Conferences

BRISBANE, Calif. and ST. LOUIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences:
Show more

Arch Oncology Blogs

A First-in-Human Study of AO-176, a Highly Differentiated Anti-CD47 Antibody, in Patients with Advanced Solid Tumors

Publication: American Society of Clinical Oncology (ASCO). Authors: Howard A. Burris III MD, FACP, FASCO, Alexander I. Spira MD, PhD, FACP, Matthew H. Taylor MD, Oladapo O. Yeku MD, PhD, FACP, Joyce F. Liu MD, Pamela N. Munster MD, Erika P. Hamilton MD, Jacob Stephen Thomas MD, Frances Gatlin , Rich…

Oppenheimer’s 31st Annual Healthcare Conference

March 16, 2021, 4:30 – 5:00 pm ET The post Oppenheimer’s 31st Annual Healthcare Conference appeared first on Arch Oncology.

Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

BRISBANE, CA and ST. LOUIS, MO, February 9, 2021 – Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors. With Encouraging Safety and Anti-tumor Activity for AO-176 Monothera…

Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020

BRISBANE, CA and ST. LOUIS, MO, December 6, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020 The post Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antib…

Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020

BRISBANE, CA and ST. LOUIS, MO, November 9, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020. Th…

Stifel 2020 Annual Healthcare Conference

Stifel 2020 Annual Healthcare Conference, November 17, 2020, 4:40 pm ET The post Stifel 2020 Annual Healthcare Conference appeared first on Arch Oncology.
Show more

Arch Oncology Frequently Asked Questions

  • When was Arch Oncology founded?

    Arch Oncology was founded in 2006.

  • Who are Arch Oncology key executives?

    Arch Oncology's key executives are John McKearn, Daniel Pereira and Arun Kashyap.

  • How many employees does Arch Oncology have?

    Arch Oncology has 28 employees.

  • Who are Arch Oncology competitors?

    Competitors of Arch Oncology include CG Oncology, Priothera and Tollys.

  • Where is Arch Oncology headquarters?

    Arch Oncology headquarters is located at 2000 Sierra Point Pkwy #700Brisbane, Brisbane.

  • Where are Arch Oncology offices?

    Arch Oncology has offices in Brisbane and St. Louis.

  • How many offices does Arch Oncology have?

    Arch Oncology has 2 offices.